The biotech news stories you need to know today

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Today, we discuss the latest with Novartis — the company reported earnings today and fielded questions about the myelofibrosis drug it got through buying MorphoSys.

Novartis hedges on filing plans for MorphoSys drug

From my colleague Drew Joseph: Last year, when MorphoSys announced Phase 3 data for its experimental myelofibrosis drug, it said it planned to file for approval for the medicine, called pelabresib. And in February, when Novartis announced it was buying MorphoSys for nearly $3 billion, the Swiss pharma giant said it planned to submit the drug to the FDA this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In